Search clinical trials for: PLX2853

Total 5 results

Opna-IO LLC

Completed

A Study of PLX2853 in Advanced Malignancies.

Follicular Lymphoma | Small Cell Lung Cancer | Solid Tumor | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Ovarian Clear Cell Carcinoma | Uveal Melanoma | Advanced Malignancies

United States
Opna-IO LLC

Completed

A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

High-risk Myelodysplastic Syndrome (MDS) | Relapsed Acute Myeloid Leukemia (AML) | Refractory Acute Myeloid Leukemia (AML)

United States
Opna-IO LLC

Terminated

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | Gynecologic Neoplasms

United States, Canada
Alliance for Clinical Trials in Oncology

Withdrawn

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Metastatic Uveal Melanoma | Advanced Uveal Melanoma | Unresectable Uveal Melanoma
Opna-IO LLC

Terminated

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States, United Kingdom

3

Subscribe